Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody

por Pan, Darren, Richter, Joshua
Publicado 2023

Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams

por Pan, Darren, Richter, Joshua
Publicado 2022

Real‐world multiple myeloma front‐line treatment and outcomes by transplant in the United States

por Richter, Joshua, Pan, Darren, Salinardi, Taylor, Rice, Megan S.
Publicado 2023

Pre-hospital antiplatelet medication use on COVID-19 disease severity

por Pan, Darren, Ip, Ada, Zhan, Serena, Wasserman, Isaac, Snyder, Daniel J., Agathis, Alexandra Z., Shamapant, Nikhil, Yang, Jeong Yun, Pai, Akila, Mazumdar, Madhu, Poor, Hooman
Publicado 2021

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma

por Pan, Darren, Kaufman, Jonathan L., Htut, Myo, Agrawal, Manish, Mazumder, Amitabha, Cornell, Robert F., Zonder, Jeffrey A., Fay, Joseph W., Modiano, Manuel R., Moshier, Erin L., Rush, Selena A., Tunquist, Brian J., Chari, Ajai
Publicado 2021

Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma

por Mouhieddine, Tarek H., Van Oekelen, Oliver, Melnekoff, David T., Li, Jeanne, Ghodke-Puranik, Yogita, Lancman, Guido, Thibaud, Santiago, Pan, Darren, Rajeeve, Sridevi, Agte, Sarita, Aleman, Adolfo, Sanchez, Larysa, Richard, Shambavi, Rossi, Adriana, Richter, Joshua, Cho, Hearn Jay, Rodriguez, Cesar, Lagana, Alessandro, Moshier, Erin, Chari, Ajai, Jagannath, Sundar, Parekh, Samir
Publicado 2022